InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright 24th Annual Global Investment Conference

September 09, 2022 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research ...

September 15, 2022
3:46 AM

September 09, 2022 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that Richard Toselli, M.D., President and Chief Executive Officer, will present at the upcoming H.C. Wainwright 24th Annual Global Investment Conference, which runs from September 12 – 14, 2022. Dr. Toselli and company management will also be available to participate in virtual one-on-one meetings with registered investors attending the conference.